Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
BMJ Open Diabetes Res Care. 2021 Dec;9(2). doi: 10.1136/bmjdrc-2021-002466.
The maximum body mass index (BMI) before onset of type 2 diabetes (MBBO) might be used to estimate a patient's insulin secretion capacity. There have been few factors that can predict future diabetic complications at the time of diagnosis of diabetes mellitus. This study aimed to clarify the clinical usefulness of MBBO for predicting the development of advanced diabetic microvascular complications.
This was a cross-sectional observational study. Of 1304 consecutively admitted patients with type 2 diabetes, we enrolled 435 patients for whom we could confirm their MBBO. Univariate and multivariate logistic regression analyses were performed to examine whether MBBO or BMI on admission was associated with advanced diabetic retinopathy or nephropathy. To evaluate the predictive performance of these indexes, we performed cross-validation in various models with MBBO or BMI and evaluated the areas under the curve (AUCs) yielded by these analyses.
Univariate analyses suggested that MBBO was associated with advanced retinopathy and nephropathy, while BMI on admission was associated only with advanced nephropathy. In multivariate analyses, MBBO was significantly associated with advanced complications, while BMI on admission was not. For advanced diabetic retinopathy, the AUCs were 0.70-0.72, and for advanced nephropathy, the AUCs were 0.81-0.83. When comparing the AUCs among models, the models with MBBO sustained high predictive performance for diabetic complications.
MBBO was independently associated with advanced diabetic complications, while BMI on admission was not. Diabetic microvascular complications in patients with high MBBO could progress more rapidly. At the time of the diagnosis of diabetes mellitus, MBBO would enable us to predict the progress of diabetic complications.
发生 2 型糖尿病前的最大体重指数(MBBO)可用于估计患者的胰岛素分泌能力。在诊断糖尿病时,能够预测未来糖尿病并发症的因素很少。本研究旨在阐明 MBBO 预测糖尿病患者发生糖尿病微血管并发症的临床价值。
这是一项横断面观察性研究。在连续收治的 1304 例 2 型糖尿病患者中,我们纳入了 435 例可确认 MBBO 的患者。采用单因素和多因素逻辑回归分析,以检验 MBBO 或入院时 BMI 是否与糖尿病视网膜病变或肾病的进展有关。为了评估这些指标的预测性能,我们在不同的模型中进行了 MBBO 或 BMI 的交叉验证,并评估了这些分析产生的曲线下面积(AUCs)。
单因素分析表明,MBBO 与糖尿病视网膜病变和肾病的进展有关,而入院时的 BMI 仅与肾病的进展有关。多因素分析表明,MBBO 与严重并发症显著相关,而入院时的 BMI 则没有。对于糖尿病视网膜病变的进展,AUCs 为 0.70-0.72,对于肾病的进展,AUCs 为 0.81-0.83。在比较模型中的 AUCs 时,包含 MBBO 的模型对糖尿病并发症具有较高的预测性能。
MBBO 与糖尿病严重并发症独立相关,而入院时的 BMI 则没有。MBBO 较高的糖尿病患者的微血管并发症可能进展更快。在诊断糖尿病时,MBBO 可以帮助我们预测糖尿病并发症的进展。